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Abstract
Background: The thyrotropin stimulating hormone receptor (TSHR) is a G protein coupled receptor (GPCR) with a large
ectodomain. The ligand, TSH, acting via this receptor regulates thyroid growth and thyroid hormone production and
secretion. The TSH receptor (TSHR) undergoes complex post –translational modifications including intramolecular cleavage
and receptor multimerization. Since monomeric and multimeric receptors coexist in cells, understanding the functional role
of just the TSHR multimers is difficult. Therefore, to help understand the physiological significance of receptor
multimerization, it will be necessary to abrogate multimer formation, which requires identifying the ectodomain and
endodomain interaction sites on the TSHR. Here, we have examined the contribution of the ectodomain to constitutive
multimerization of the TSHR and determined the possible residue(s) that may be involved in this interaction.
Methodology/Principal Findings: We studied ectodomain multimer formation by expressing the extracellular domain of
the TSHR linked to a glycophosphotidyl (GPI) anchor in both stable and transient expression systems. Using co-
immunoprecipitation and FRET of tagged receptors, we established that the TSH receptor ectodomain was capable of
multimerization even when totally devoid of the transmembrane domain. Further, we studied the effect of two residues
that likely made critical contact points in this interaction. We showed that a conserved tyrosine residue (Y116) on the convex
surface of the LRR3 was a critical residue in ectodomain multimer formation since mutation of this residue to serine totally
abrogated ectodomain multimers. This abrogation was not seen with the mutation of cysteine 176 on the inner side of the
LRR5, demonstrating that inter-receptor disulfide bonding was not involved in ectodomain multimer formation.
Additionally, the Y116 mutation in the intact wild type receptor enhanced receptor degradation.
Conclusions/Significance: These data establish the TSH receptor ectodomain as one site of multimerization, independent
of the transmembrane region, and that this interaction was primarily via a conserved tyrosine residue in LRR3.
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Introduction
The thyroid stimulating hormone receptor (TSHR), a typical 7-
transmembrane GPCR, on the surface of thyrocytes, is the master
regulator of thyroid growth and development. TSH acting via
TSHR regulates thyroid hormone production and secretion. In
addition TSHR is also a major autoantigen for autoimmune
diseases of the thyroid gland [1–4]. The TSHR consists of a large
extracellularectodomain of415residuesinclusiveofa signal peptide
of 21aa. The 10 leucine rich repeat regions (LRR) on the
ectodomain is the main region for TSH and TSHR antibody
binding. The membrane associated intracellular carboxyl terminal
endodomain of 384aa encoded by the 10th exon consists of the 7
transmembrane domains and a short cytoplasmic tail [5]. Unlike
other glycoprotein hormone receptors, this receptor has a unique 50
amino acid region (residues 316–366) on its extracellular domain
which undergoes proteolytic degradation[6] by an unidentified
matrix metalloprotease resulting in the cleavage of the receptor into
a (or A) and b (or B) subunits held together by disulfide bonds [7–9].
It is well established that GPCRs may exist as dimers and higher
order complexes such as oligomers/multimers [10–12]. The
TSHR, in addition to undergoing intramolecular cleavage, also
exists as dimers and higher order forms both in native tissue and
transfected cells [13–15]. Our laboratory not only showed the
existence of these higher order complexes in native porcine
membranes and in heterologous cells [13,14] but also observed
that these di(multi)meric complexes were regulated by TSH ligand
[16], a phenomenon that appeared to be exaggerated for TSHRs
residing in ‘‘lipid rafts’’ [17] - cholesterol and sphingolipid rich
domains on the plasma membrane.
TSHR homodimerization, confirmed by Foster Resonance
Energy Transfer (FRET) and Bioluminescence Resonance Energy
Transfer (BRET), has been shown to play a functional role in
negative cooperativity by allosteric modulation [15]. Although the
phenomenon of negative cooperativity with TSHRs was well
known earlier [18,19], the phenomenon can be explained by
the observation that the TSHR is capable of existing in dimeric
and multimeric forms [15]. Another functional role for TSHR
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9449dimerization has been in the mechanism of TSH resistance seen in
congenital hypothyroidism. Trafficking of the wild type receptor to
the cell surface was inhibited when co-expressed with a mutant
TSHR [20,21]. We have also observed that cross-linking the
TSHRs, using receptor specific monoclonal antibodies, appeared
to reduce intra-molecular cleavage of the receptors which in turn
prolonged their cell surface expression [22]. This observation has
possible implications for the prolonged stimulation of the TSHR
autoantigen [22]. Furthermore, although multimerization has not
been proven to be directly involved in receptor signaling, we have
observed that TSHR multimers are enriched in ‘‘lipid rafts’’
coexisting with G proteins and monomers [17]. These observa-
tions suggest that it may take both monomeric and multimeric
forms of receptor to coexist for the normal physiological functions
of thyrocytes as suggested for other GPCRs [23].Therefore the
role of higher order forms of the TSHR in physiology and
pathology of the thyroid remains open to investigation.
Co-existence of monomeric and di (oligo) meric forms of
TSHRs on the thyroid cell surface makes it difficult to delineate
the precise role of each form in signal transduction or receptor
trafficking. Furthermore, cleaved and uncleaved forms of the
receptor are capable of aberrant homodimerization [24] and
influence receptor signaling adding to the complex nature of
receptor interactions. Therefore, to study the impact of these
higher order receptors, it will be necessary to first try and inhibit
constitutive dimerization/multimerization and then examine the
physiological consequences of such inhibition. We have, therefore,
begun to define the dimerization interfaces by determining the
contact points on the large ectodomain. The Follicle Stimulating
Hormone (FSH) receptor, which has a similarly large ectodomain,
when devoid of the transmembrane domain, was still capable of
dimerization [25] when the first 268 amino acids of the
ectodomain were crystallized in the presence of FSH. Following
the FSH crystal structure, the TSH receptor extracelluar domain
(TSHR260) complexed with a TSHR antibody (M22) Fab has
been solved to a resolution of 2.55A [26]. Hence, we hypothesized
that the TSHR extracellular domain may harbor dimerization
motifs and in this report we confirm that 1) The TSHR
ectodomain is indeed capable of forming higher order complexes
independent of its transmembrane domain, 2) We defined the
major contact point for this interaction and 3) We analyzed the
role of the contact residues in receptor stability.
Results
Surface Expression of GPI-TSHR-ECD Constructs
To study the role of the extracellular portion of the TSHR in
constitutive dimerization/multimerization, we used the TSHR
ectodomain (1-412aa) linked to a GPI anchor. The cDNA
construct was stably expressed in Chinese Hamster Ovary
(CHO) cells (CHO-GPI-TSHR-ecd) and also transiently expressed
in Human Embryonic Kidney (HEK) 293 cells. We first tagged the
amino terminus of the GPI-TSH-ecd receptors (with HA or Myc)
and assessed their expression on the cell surface of transiently
transfected HEK293 cells. This was confirmed by staining unfixed
cells using anti-HA or anti-Myc monoclonal antibodies by flow
cytometry (Figure 1). These studies demonstrated a good degree of
expression with a Mean Fluorescence Intensity (MFI) of .250AU
for each of these tagged constructs with 65% of cells positive for
HA and 25% of cells positive for Myc expression
Existence of Higher Order Forms of TSHR Ectodomain
We next analyzed total membranes prepared from CHO-GPI-
TSHR-ecd [16] (G13 cells) with and without TSH exposure and
under non-reducing and reducing conditions. The blots when
probed with a TSHR antibody M4 (RSR 4: recognizing residue
322–341) [27], revealed the presence of higher order forms in
addition to the fully mature monomeric form of GPI: TSHR–Ecd
Figure 1. Expression profile of HA and Myc tagged GPI-TSHR-ecd receptors: HEK293 cells were transiently transfected with 1 ug of HA or
Myc-GPI-TSHR-ecd plasmid cDNA and the cells were stained 48 hrs post-transfection with anti-HA or anti-Myc (1 ug/10
6cells) antibody. This was
followed by anti-mouse IgG Fab’ conjugated to phycoerthrin (PE) as secondary antibody. Density analysis for receptor expression under FL2 (PE) and
FL1 (FITC) was performed using the Beckman Lab Quanta SC flowcytometer. Panel A) Controls cells transfected with vector only and stained with
primary and secondary antibodies. Panel B) HA-GPI-TSHR-ecd transfected cells stained with anti-HA (66% positivity). Panel C) Myc-GPI-TSHR-ecd
transfected cells stained with anti-myc (25% positivity). Since tags are the N-terminus of the receptor ectodomain, unfixed cells were used for this
staining.
doi:10.1371/journal.pone.0009449.g001
TSHR Multimerization
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molecular species of 74KD as observed by others [28]. Distinct
bands of 250KD corresponding to higher order forms of the
ectodomain was observed in untreated and TSH treated samples
under non-reduced conditions (Figure 2A). However, reduction of
these samples with 100 mM DTT for 45 minutes at 50uC, caused
the multimeric forms as well as the 100KD form to be reduced into
less mature form of the TSHR ectodomain (Figure 2B). This was
observed even in transiently transfected HEK 293 cells as shown in
Figure 3A and 3B. Previously we had observed that TSH treatment
of full length receptors stably expressed in CHO cells caused a
marked decrease in multimeric forms both in total membranes and
lipid raft preparations under non-reducing conditions [17]. This
lack of effect of TSH on ectodomain expression was confirmed by
flow cytometry (Figure 3C).
Homo-Interaction of TSHR Ectodomains and the Effect of
Tyrosine (Y116) and Cysteine (C176) Mutations
Molecular modeling and bioinformatic approaches have clearly
shown that transmembrane domains are the potential regions of
dimerization ormultimerization of several GPCRS [29,30] although
the role of the ectodomain in this process of receptor-receptor
interaction is still unclear. To extend our observations on multimers
observed in non-reduced conditions and to study the effect of
mutations on the interaction of receptors, we used co-immunopre-
cipitation of the tagged TSHR ectodomain receptor constructs.
We mutated residues corresponding to C176 and glycoprotein
receptor conserved Y116on the ectodomain of the HA-GPI-
TSHR-ecd construct into alanine and serine respectively. The
location of residues Y116 and C176 are indicated on the structural
model of the receptor ectodomain in Figure 4A. The mutated
Figure 2. Immunoblot of total membranes under reduced and non-reduced conditions from stably transfected cells: CHO cells stably
expressing GPI-TSHR-ecd were treated with 0, 10 and 1000 mU/ml of bovine TSH for 1 hr at 37uC. Membranes prepared from untreated and treated
cells was divided into 30 ug/lane and treated with 5X sample buffer containing reducing agent (+DTT: 100 mM final) and non-reducing agent (-DTT)
and separated on a 12% SDS-PAGE. Proteins were transferred onto PVDF and probed by 2 ug/ml TSHR antibody M4 (epitope 322–341) followed by
detection with anti-mouse HRP (1:20,000) and developed using pico SuperSignal ECL (Pierce Ltd). Panel A) Shows the non-reduced untreated and
treated samples. Oligomeric forms of 200–250 KD were observed in addition to the mature 100KD and less mature 75 KD monomeric forms GPI
linked TSHRs. Panel B) Untreated and treated samples after reduction with DTT for 45 minutes at 50uC showing no higher order forms of the TSHR-
ecd indicating the instability of the TSHR-ecd higher order forms. This is a representative blot from two experiments performed under identical
conditions. Panel C) the specificity of the antibody M4 used for immunoblotting throughout the study is indicated in this blot. Lysates from
untransfected HEK 293 cells and TSHRGFP transfected wild type cells were resolved on SDS-PAGE and immunblotted with 2 ug/ml of M4 antibody.
M4 did not have any reactivity with untransfected lysate as opposed to TSHR transfected lysate where it detected the monomeric and multimeric
forms of the receptor.
doi:10.1371/journal.pone.0009449.g002
TSHR Multimerization
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The expression of these mutant receptor forms was also verified on
unfixed and fixed cells by flow cytometry using anti-HA and
TSHR specific monoclonal antibody M1 (recognizing residues
381–385) as described above (Figure 4B). Furthermore, mem-
branes prepared from single and double transfected cells were
immunoprecipitated with anti-Myc and the immunoprecipitates
were analyzed with anti-HA. Ectodomain-ectodomain interaction
was confirmed when we observed that anti-myc pulled down the
less mature 75KD receptor complex when probed with anti-HA in
membrane preparations from HA-GPI-TSHR-ecd+Myc-GPI-
TSHR-ecd co-transfected cells. In contrast, no immunoprecipi-
tates were observed from membranes of single transfected HA-
GPI-TSHR-ecd cells (Figure 4C, Lanes 1 & 2). However,
immunoprecipitation of membranes of HA-GPI-TSHR-ecd with
Y116 mutation + Myc-GPI-TSHR-ecd also failed to result in the
75KD protein (Lane 4) in contrast to 75KD protein band observed
in membranes from C176 mutated HA-GPI-TSHR-ecd +
MycGPI-TSHR-ecd transfected cells (Lane 3). Other controls
such as the Y116 mutated HA-GPI-TSHR-ecd single transfected
cells and untransfected membranes did not yield any protein
bands corresponding to these receptor sizes.
These data further confirmed the interaction of TSHR ectodo-
mains. The results also demonstrated Y116 on the outer alpha helix
loop of LLR3 as a critical interacting partner since mutation of this
residue to serine abrogated ectodomain-ectodomain interactions.
Homo-Interaction of TSHR Ectodomain in Live Cells
The biochemical evidence of ectodomain interaction observed
above was confirmed in live cells. HEK 293 cells transfected with
HA-GPI-TSHR-ecd + Myc-GPI-TSHR-ecd were used for FRET
studies. FRET was performed using anti-HA FITC as the donor
moleculeandanti-MycCy3asacceptormolecule.Cellslabeledwith
donor alone and acceptor alone were used as endogenous controls
for this FRET studies. In each experiment, data acquired from five
single transfected and double transfected cells were analyzed for
FRET efficiency after removal of background and spectral bleed-
through by using the pFRET software [31]. We were able to
Figure 3. Immunoblot of total membranes under reduced and non-reduced conditions from transiently transfected HEK cells: HEK
293 cells transiently transfected with HA-GPI-TSHR-ecd were treated with 0, 10 and 1000 mU/ml of bovine TSH for 1 hr at 37uC. Total membranes
prepared from untreated and treated cells were divided into 30 mg/lane and treated with 5X sample buffer containing reducing agent (+DTT:100 mM
DTT final) and non-reducing agent (-DTT) and the proteins separated by 12% SDS-PAGE. The blots were probed further using 2 mg/ml TSHR antibody
M4 (epitope 322–341) followed by detection with anti-mouse HRP (1:20,000) and developed using pico SuperSignal ECL (Pierce Ltd). Panel A) Shows
the untreated and TSH treated samples under non-reduced conditions. Panel B) The same set of samples as in Panel A after reduction with DTT for
45minutes at 50uC. Results are similar to that observed with stably expressed cells in Figure 2. Panel C) Flow cytometric data of untreated versus
treated cells. TSH treatment did not alter the expression profile of HA in these HA-GPI-TSHR-ecd transiently transfected cells. The expression levels of
the tagged receptor are indicated by their mean fluorescence intensity (MFI).
doi:10.1371/journal.pone.0009449.g003
TSHR Multimerization
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+ Myc-GPITSHR-ecd transfected cells which was lower than the
control cells with full-length receptors tagged at their carboxyl end
with GFP as donor and Myc antibody labeled with Cy3 as an
acceptor (FRET efficiency of 20–25%, Figure 5). There was no
FRET in single transfected cells. The FRET data on these N-
terminus tagged GPI-TSHR-ecd cells further confirmed the
interaction of ectodomains observed with immunoprecipitation.
Y116 Mutation on Wild Type TSHR Leads to Receptor
Degradation
To study if the Y116 mutation had any effect on receptor
degradation in the context of the transmembrane region, we
mutated Y116 to serine on the full length TSHRGFP. FRET
efficiency between the Y116 mutated TSHRGFP construct and the
Myc labelled non-mutated TSHRmyc tagged full-length (WT)
Figure 4. Co-immunoprecipitation of HA and Myc tagged TSHR ectodomain and its mutants: A) the position of Y116 and C176 are
indicated on the ECD structure. Y116 is on the outer convex surface of the LRR3 (red) and C176 (green) is on the concave inner surface of the LRR5.
The coordinates for the ectodomain structure of TSH receptor was obtained from the GRIS database [43] and this structure was examined in the open
source molecular graphics program VMD (www.ks.uiuc.edu/Research/vmd) to mark the position of Y116 and C176 on the ECD structure. B)
Expression of the Y116 on HEK 293 cells is indicated both microscopically and quantitatively by flow cytometry. The yellow staining observed on the
cell surface was due to double staining of GFP (on the C-terminus of construct) and TSHR antibody (RSR1 or M1 residue 381–385) labeled with
secondary antibody conjugated to texas red. The FACS profiles on right shows that 78% of these cells to be double positive. The C176 construct
expressed on HEK 293 had similar levels of expression (data not shown). C) as described above, constructs carrying the Y116 or C176 mutations (in
the HA-GPI-TSHR-ecd) were co-transfected with Myc-GPI-TSHR-ecd. Membranes prepared from single and double transfected cells were
immunoprecipitated using anti-Myc monoclonal antibody 9E10 (2 mg/ml final). The PVDF transferred immune complex was probed with anti-HA
(1 mg/ml) and developed further with secondary antibody conjugated to HRP. Lane 1) Membranes from single transfected cells (HA-GPI-TSHR-ecd
only) and subjected to identical co-immunoprecipitation conditions. Lane 2) Membranes from double transfected cells (HA-GPI-TSHR-ecd+Myc-GPI-
TSHR-ecd). Lane3) Membranes from double transfected cells (C176D HA-GPI-TSHR-ecd+Myc GP-TSHR-ecd). Lane 4) Membranes from double
transfected cells (Y116 D HA-GPI-TSHR-ecd + Myc-GPI-TSHR-ecd). Lane 5) Membranes from single transfected cells (C176D HA-GPI-TSHR-ECD only).
Lane 6) Membranes from single transfected cells (Y116 mutant HA-GPI-TSHR-ecd only) and Lane 7) Membranes from untransfected HEK293 cells.
Only monomeric forms are seen with immunoprecipitation and reduction in lanes 2 and 3. Mutation of Y116 caused loss of receptor interaction and
higher order forms and thus no immunoprecipitation of TSHR-ecd (lane 4).
doi:10.1371/journal.pone.0009449.g004
TSHR Multimerization
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We further studied the structural forms of the receptor in total
membranes under non-reduced condition to examine if the
decrease in FRET was due to receptor degradation. Y116
mutated receptor preparations showed lower molecular weight
degraded forms (Figure 7B) which increased with time of TSH
treatment. No degraded forms were observed in the non mutated
WT receptor membrane preparations even after 30 minutes of
TSH treatment (Figure 7A). These data suggested a role for Y116
in receptor stability. A control mutation, isoleucine 117 (I117), in
the outer loop of LLR3 adjacent to Y116 also did not lead to any
increased constitutive receptor degradation. (Figure 7C).The
cAMP signaling capability of Y116 receptor, however, was not
affected by the enhanced degradation of the receptor forms
(Figure 7D) suggesting ectodomain degradation was post-signaling.
Discussion
Glycoprotein hormone receptors such as the LHR, FSHR and
TSHR belonging to Class A receptors exist as dimeric and higher
order forms in native and transfected cells [13–15,32–34] although
the physiological relevance of these receptor forms is still under
investigation. Therefore, to understand the exact biological role of
dimers and/or higher order forms of receptors it will be necessary
to generate GPCRs that are expressed only as monomeric or
multimeric receptor forms in model cell systems. This requires
mapping the several dimerization/multimerization interfaces of
the receptors and to mutate the critical interface residues without
compromising the function of these receptors. While we, and
others, have shown previously that the transmembrane region of
the TSHR is the major region of dimer or oligomer formation
Figure 5. FRET on HA and Myc tagged ectodomain constructs in HEK 293 cells. HA-GPI-TSHR-ecd and myc-GPI-TSHR-ecd were co-
transfected into HEK 293 cells and stained with anti-HA FITC and anti-Myc Cy3 labeled antibody and imaged for energy transfer between FITC (donor)
and Cy3 (acceptor) fluorophores. As described in Materials and Methods single transfected cells labeled with anti-HA-FITC and anti-Myc-Cy3 alone
were the endogenous control for lack of FRET and for correction of donor and acceptor spectral bleed through. Panel A shows the staining of GPI-
TSHR-ecd by anti HA FITC. Panel B shows the same cell stained with anti Myc Cy3. Panel C is the pseudo colored FRET energy level image obtained
from the analysis of the double transfected cells by using the pFRET software. The calibration bar indicates the FRET energy t level in the cell. Energy
transfer was in the range of 8–10% on the surface of the cells compared to controls (TSHRGFP +TSHRmyc labeled with Cy3) which showed energy
transfer of 24%.
doi:10.1371/journal.pone.0009449.g005
TSHR Multimerization
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in receptor- receptor interaction and stabilizing such receptor
forms has not been delineated. The present study, therefore, was
designed primarily to understand this role of the ectodomain on
receptor-receptor interaction.
We expressed untagged and tagged TSHR ectodomains
(residues 1–412) in mammalian cells and found higher order
forms of the receptor under non-reduced conditions. That these
forms resulted secondary to interaction of the ectodomain
receptors in vivo was confirmed by the FRET analyses. Hence,
the data demonstrated that TSHR ectodomains were capable of
forming higher order forms in the absence of the transmembrane
domain. However, these higher order forms of ectodomain were
unstable on mild reduction with DTT. While it is not uncommon
for DTT to have nonspecific effects on the dissociation of whole
receptor complexes as observed with the P2Y12 and b2AR
GPCRs [35,36], the reduction of higher complexes by DTT
suggested that ectodomain oligomer formation may be mediated,
in part, by disulfide bond formation via the several cysteine
residues found on the ectodomain of the TSHR [1,6]. It has been
established that 10 of the 11 cysteine residues in the ectodomain of
the TSHR pair with each other resulting in 3 cysteine boxes [1,6].
This arrangement leaves C176, located on the inner side of the
concave surface of the leucine rich region (LRR), as the only
unpaired cysteine. Being the only unpaired cysteine, we speculated
that cysteine 176 (C176) may be a potential candidate for the
formation of intermolecular disulfide bond formation. This
justified our choice of cysteine 176 as a possible residue to mutate.
Since disulfide bond formation is not the only mechanism of
oligomer formation in GPCRs [10,37] we also examined tyrosine
116 located on the outer loop of LRR 3 based on the reported
crystal structure of the FSH-FSHRHB existing as a biologically
plausible dimer contact point [25]. This study of the FSHR
showed that Y116 was conserved among LHR, FSHR and
TSHRs with a 0.1 fractional solvent accessibility score which
suggested it may be a critical residue in the dimer interface. We
had earlier established, by biochemical and biophysical approach-
es, that the full length TSHR is able to form dimeric and higher
order forms in native and transfected cells [13,16,17]. These di-
(oligo)meric forms of TSHR resided on the surface of the cells as
shown by FRET using reporter tagged receptors and HFRET
using donor and acceptor labeled antibodies [15,16]. Studies on
oligomer formation in GPCRs has largely focused on the
involvement of either full-length receptors or the transmembrane
regions with very few reports of extracellular amino-terminal
domain involvement [37–39]. The present study clearly demon-
strated that TSHR ectodomains, independent of their transmem-
brane regions, could form higher order oligomers. Using
differentially tagged GPI-TSHR-ecds, we succeeded in confirming
this phenomenon using co-immunoprecipitation and FRET on
live cells. Although the FRET efficiency in ectodomain expressing
cells was lower compared to the data obtained with full-length
TSHRs this was most likely due to the combined use of two
labeled antibodies which can result in unfavorable dipole
orientations.
To study the effect of the two potentially important residues in
ectodomain multimers, we mutated C176 in LRR5 and Y116
in LRR3 to serine in the tagged constructs. The two mutated
receptors showed no obvious trafficking abnormality and were
detected on surfaces of unfixed cells. Furthermore, co-immuno-
precipitation of membranes prepared from double transfected cells
showed that mutation of C176 did not abrogate the receptor-
receptor interaction. However, mutation of Y116 to serine
resulted in the loss of receptor-receptor interaction leading to no
immunoprecipitation. It has been recently shown that the FSHR
ectodomains in the FSH-FSHRHB crystal structure also interact to
constitute a dimer [25]. According to this study the dimer interface
involved three stranded b-sheets (LRR 2-4) on the outer surface of
the FSHRHB and Y116 contributed to a strong hydrophobic
interaction mediating 21 of the 24 direct carbon-carbon contacts
[25]. Since Y116 is completely conserved among the glycoprotein
hormone receptors, it was important to examine this residue in the
context of receptors expressed on the cell surface in the absence of
the transmembrane domain. Looking at the structural details of
the TSHR ectodomain in the GRIS database (http://gris.ulb.ac.
be) we found that Y116 makes a hydrogen bond with residue Asp
65 (3061) and several hydrophobic contacts although there are no
salt bridges reported for this residue further suggesting the
interactions to be weak. However, a follow up study on the
structural determinants of FSHR dimerization showed that
mutation of Tyr110 to alanine did not inhibit dimerization [40].
Although the FSHR and the TSHR belong to the same family of
glycoprotein receptors and have presumably similar ligand
binding orientation [26] the discrepancy with the study of Guan
et al [40] can only be due to the following differences 1) We
employed ECD constructs tagged at the amino terminus with HA
and myc to do our co-IP and FRET studies rather than
transmembrane linkers such as LRP6 and CD8 tagged at their
cytoplasmic end with donor acceptor pairs. The short GPI anchor
to the ectodomain may have provided it the ability to orient more
freely on the plasma membrane. 2) The TSHR has a unique 50
amino acid region in its ectodomain which undergoes proteolytic
cleavage. The proteolytic cleavage of the ECD may have
weakened the interaction by orienting the ECD differently
between the ectodomain partners making it susceptible to point
mutational changes. The recently solved crystal structure of the
TSHR complexed with M22 Fab showed no evidence of dimer
formation [26] as opposed to the weak dimerization observed
between the FSH-FSHR structures [25]. If these differences are
Figure 6. Effect of Y116 mutation on receptor. FRET efficiency of
Y116 and full length TSHR are indicated at low and high acceptor
values. Y116 shows decreased FRET efficiency compared to the WT type
cells.
doi:10.1371/journal.pone.0009449.g006
TSHR Multimerization
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the Fab fragment of receptor antibody [16] remains to be explored
further.
To examine if residue Y116 had any role on receptor stability
we studied receptor degradation in the presence and absence of
this mutation. As a control we included another residue, a leucine
I117, adjacent to Y116 and which is also on the outer loop of
LLR3. The presence of the Y116 mutation induced degradation of
the receptor but the degradation was not strong enough to cause a
change in signal transduction i.e cAMP response although it is not
know if this would affect other receptor functions such as
internalization and down regulation.
In conclusion, the present study demonstrated that the TSHR
ectodomain is capable of forming higher order multimers even in
the absence of the transmembrane region. Furthermore, Y116, a
conserved tyrosine residue on LRR3 of TSHR, was a major
contributor to the ectodomain interactions and had a role in the
stabilization of the receptor. Nevertheless, since the Y116
mutation did not abrogate multimerization in the full length
receptor, the transmembrane region interactions must be the more
dominant force.
Materials and Methods
Epitopes Tagging of GPI-TSHR ECD DNA
In order to perform co-immunoprecipitation and in vivo FRET
studies using a GPI linked TSH receptor ectodomain construct
(GPI-TSHR-ecd), we inserted HA or Myc epitope tags on the N -
Figure 7. Effect of Y116 mutation on receptor degradation. Panels (A, B and C) Solubilized receptors separated under non-reduced
conditions from TSHRYFP (WT), Y116 and I117 mutated receptor transfected cells at 0 and 30 minutes after 1000 mU/ml of bovine TSH. The Y116
mutated receptors showed enhanced degraded forms of 60KD to 20KD which was not observed with the wild type receptor nor I117 mutated
receptors. Panel D: HEK 293 cells transfected with the WT receptor (TSHRYFP) and Y116 mutated receptor where stimulated with varying doses of
bovine TSH. A dose-dependent cAMP response of the two receptors is shown in the graph. Y116 mutation on ectodomain had no effect on the
response of receptors to TSH.
doi:10.1371/journal.pone.0009449.g007
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immediately after the signal peptide sequence in the GPI-
TSHR-ecd cDNA using the method of inverse PCR mutagenesis
[41]. After ligation, the PCR product was Dpn I enzyme digested
to remove the parent methylated DNA and transformed into
INFa’ bacteria (Invitrogen) and the positive clones were picked by
PCR with HA (human influenza hemagglutinin protein) or Myc
(c-myc is a family of nuclear protein found in human tumors) as
forward primers and a TSHR gene specific reverse primer. The
positive clones were sequence verified for insertion and correct
orientation of the epitope tag.
Cell Culture and Transfection
TSHR ectodomain construct (residues 1–412) linked to GPI
(GPI-TSHR-ecd) provided by Dr. A.P Johnstone, St. George’s
Hospital Medical School, UK, [42] was transfected into Chinese
Hamster Ovary (CHO) cells to make a stable line, named G13
cells. These cells were maintained in Hams-F12 with 10% FBS,
100 units of penicillin/streptomycin and 600 ug/ml of G418. For
transient transfection experiments, we used human embryonic
kidney (HEK) 293 cells obtained from the ATCC. These cells were
grown in DMEM with 10% FBS, 100units of penicillin/
streptomycin until transfection. The cells were seeded to obtain
80–90% confluence prior to transfection and different doses of
DNA were transfected using Lipofectamine 2000 (Invitrogen) as
per the manufactures protocol. For FRET studies the cells were
seeded in 0.1% collagen precoated Delta T dishes (0.3610
6/dish)
and transfected with the respective donor and acceptor tagged
constructs single or double transfected. 48 hrs post-transfection the
cells were stained using either anti-HA conjugated to FITC or
anti-Myc conjugated to Cy3 (1:100 dilution).
Staining & Expression
The expression of the tagged constructs on the surface of
transfected HEK 293 was confirmed by staining unfixed cells with
primary antibody (anti-HA MAb and anti-Myc Mab) at 1 mg/10
6
cells. This was followed by secondary anti mouse (Fab’) conjugated
to phycoerythrin (PE) (Jacksonimmuno Research Inc) at 1:200
dilution. Non-transfected and vector alone transfected cells stained
with primary and secondary antibodies and secondary antibody
alone were used as controls in the assay. The stained cells were
analyzed under the FL2/PE channel (575 nm) on a Beckman
Coulter Cell Lab Quanta SC flow cytometer.
Immunostaining and FRET
Transiently transfected cells on Delta T dishes were fixed with
4% paraformaldehyde for 30 minutes at RT and then stained with
anti HA conjugated to FITC or anti Myc conjugated to Cy3 in
PBS containing 2%FBS for 1 hr. The cells were thoroughly
washed with PBS and mounted using Vectashield. Individual
dishes with anti-HA FITC as donor (D), anti-Myc Cy3 as acceptor
(A) and cells co-transfected with HA and Myc tagged DNA and
stained with anti HA FITC plus anti Myc Cy3 as double labeled
cells (DA) were used for sensitized emission FRET studies on a
Nikon TE 2000-S microscope consisting of emission and excitation
FRET filter wheels controlled by In-Vivo software (Media
Cybernetics Inc). The four sets of images that were acquired from
each stained dish were as follows: 1) Donor excitation-Donor
Emission (Dex-Dem), 2) Acceptor excitation-Acceptor emission
(Aex-Aem), 3) Donor excitation-Acceptor emission (Dex-Aem) and
4) Acceptor excitation- Donor emission (Aex-Dem). A minimum of
5 cell images from each of the above stained dishes was acquired
for FRET efficiency (%) calculations. Using the pFRET software,
background subtraction and donor spectral bleed through (DBST)
and acceptor spectral bleed through (ABST) were subtracted from
the acquired images to give the corrected FRET image and
efficiency calculations. The wild type receptor tagged with either
GFP or Myc at its carboxyl end were used in the same
configuration as mentioned above as positive controls because
these receptor constructs have been shown to homodimerize by
our previous FRET studies [14,16].
TSH Treatment and cAMP Generation
For dissociation studies and cAMP generation, bovine TSH was
used (Sigma). The cells were treated in complete medium with 0
and 10
3 mU/ml of TSH for 30 minutes at 37C for dissociation and
for cAMP estimation cells were treated with 0, 10,10
2,10
3, and
10
5 mU/ml of TSH for 1 hr at 37uC. For membrane preparations,
the cells were washed immediately with ice cold PBS and chilled
on ice for 15 minutes and then prepared by the digitonin method
as described earlier [16].For cAMP assays the cells were lysed and
an EIA performed as per the instructions of the manufacturer (GE
Healthcare Amersham cAMP Biotrak EIA system Cat
#RPN225).
Point Mutations of ECD
Point mutations of Y116 and C176 were introduced by using
the Phusion site-directed mutagenesis kit (BioLabs). The protocol
from the manufacturer was followed in order to introduce the
mutation into the cDNA template of human TSHR. The primer
sequences used for introducing the Y116 mutation were 1)
Forward primer: 59-AACTTAACTG-CCATAGACCCTGAT-
392) Reverse primer: 59ATCAGGGTCTATGGCA GTTAA-
GTT-39 and for Cystein 176 mutation 1) Forward primer: 59-
AGTAATGAAACCTTGACACTGAAG-39 and 2) Reverse
primer: 59-ACTTAGTCCCTGAAAAGCATTCAC-39. All mu-
tations were sequence verified and expressed transiently in
HEK293 cells to verify surface expression of the mutated protein.
A similar approach was used to introduce a conserved point
mutation of residue alanine 111 as a nonspecific mutation on the
outer loop of LLR3.
Total Membrane Preparation
CHO-GPI-TSHR-ecd (G13) stable cells were seeded at a
density of 5610
6 cells per 100 mm dish and allowed to grow to a
density of 100% in Ham F12 medium with 10% FBS and
antibiotics prior to treatment with TSH. For transient transfection
of HEK 293 cells, the cells were seeded at a density of 7-8610
6/
100 mm dish and allowed to grow overnight to a density of 80–
90% before transfecting then with HA-GPI-TSHR-ecd or Myc-
GPI-TSHR-ecd or both DNAs. Membranes from test and control
cells were prepared as previously described using the digitonin
method [16].
Co-Immunoprecipitation and Immunoblotting
Membranes prepared from transiently transfected cells of HA-
GPI-TSHR-ecd, Myc-GPI-TSHR-ecd, double transfected cells
such as HA-GPI-TSHR-ecd+Myc-GPI-TSHR-ecd and Y116
mutation HA-GPI-TSHR-ecd + Myc-GPI-TSHR-ecd and C176
mutation HA-GPI-TSHR-ecd+Myc-GPI-TSHR-ecd were immu-
noprecipitated with anti-myc (9E10 MAb). Briefly, fractions were
precleared with protein-A agarose beads for 30 minutes at 4uC.
The precleared supernatant was collected into fresh tubes and
precipitated by the addition of 1 mg/ml of monoclonal Myc
antibody for 3 hr at 4uC. This was followed by a pull down of the
immune complex with protein-A beads. The immunoprecipitates
were then solubilized with 100 mM of DTT for 45 minutes at
TSHR Multimerization
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PVDF membranes. Membranes were blocked with 5% dried
skimmed milk in TBS (Tris Borate Saline) containing
0.05%Tween-20 (TBST) and then probed with 2 mg/ml mono-
clonal anti-HA for 1 hr at room temperature. Washed membranes
were then incubated with 1:5000 of secondary antibody (anti-
mouse HRP) for 1 hr at room temperature. After final washing,
bound secondary antibodies were visualized using enhanced
chemiluminescence (Super Signal ECL, Pierce, and IL).
Acknowledgments
We thank Dr. Mihaly Mezei, Department of Structural and Chemical
Biology, Mount Sinai School of Medicine, New York for help with
ectodomain structural model and Dr Ammasi Periasamy, W.M Keck
Center for Cellular Imaging, University of Virginia, VA, USA for
providing the plug-in for the pFRET software. We also thank Drs Annie
Baliram, Risheng Ma and Xiaoming Yin for critical reading of this
manuscript. Mr. Zhong Yao provided technical assistance in transfection
assays and cell culture.
Author Contributions
Conceived and designed the experiments: RL. Performed the experiments:
RL KM SAM. Analyzed the data: RL TFD. Wrote the paper: RL.
Provided the funds for the study and oversaw the design, execution of
experiments, analysis and writing of the paper: TFD.
References
1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM (1998) The
thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr
Rev 19: 673–716.
2. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD (2002) Thyroid-
stimulating hormone and thyroid-stimulating hormone receptor structure-
function relationships. Physiol Rev 82: 473–502.
3. Terry Davies, Russell Marians, Rauf Latif (2002) The TSH receptor reveals
itself. J Clin Invest 110: 1–4.
4. Vassart G, Dumont JE (1992) The thyrotropin receptor and the regulation of
thyrocyte function and growth. Endocrine Reviews 13: 596–611.
5. Davies TF, Ando T, Lin RY, Tomer Y, Latif R (2005) Thyrotropin receptor-
associated diseases: from adenomata to Graves disease. J Clin Invest 115:
1972–1983.
6. Chazenbalk GD, Tanaka K, Nagayama Y, Kakinuma A, Jaume JC, et al. (1997)
Evidence that the TSh receptor ectodomain contains not one, but two, cleavage
sites. Endocrinology 138: 2893–2899.
7. Couet J, Sar S, Jolivet A, Hai M-TV, Milgrom E, et al. (1996) Shedding of
human TSH receptor ectodomain: involvement of a matrix metalloprotease.
Journal of Biological Chemistry 271: 4545–4552.
8. de Bernard S, Misrahi M, Huet JC, Beau I, Desroches A, et al. (1999) Sequential
cleavage and excision of a segment of the thyrotropin receptor ectodomain. J Biol
Chem 274: 101–107.
9. Kaczur V, Puskas LG, Nagy ZU, Miled N, Rebai A, et al. (2007) Cleavage of the
human thyrotropin receptor by ADAM10 is regulated by thyrotropin. J Mol
Recognition 20: 392–404.
10. Breitwieser GE (2004) G protein-coupled receptor oligomerization: implications
for G protein activation and cell signaling. Circ Res 94: 17–27.
11. Hebert TE, Bouvier M (1998) Structural and functional aspects of G protein-
coupled receptor oligomerization. Biochem Cell Biol 76: 1–11.
12. Szidonya L, Cserzo M, Hunyady L (2008) Dimerization and oligomerization of
G-protein-coupled receptors: debated structures with established and emerging
functions. J Endocrinol 196: 435–453.
13. Graves PN, Vlase H, Bobovnikova Y, Davies TF (1996) Multimeric complex
formation by the natural TSH receptor. Endocrinology 137: 3915–3920.
14. Latif R, Graves P, Davies TF (2001) Oligomerization of the human thyrotropin
receptor: fluorescent protein-tagged hTSHR reveals post-translational complex-
es. J Biol Chem 276: 45217–45224.
15. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, et al. (2005) Glycoprotein
hormone receptors: link between receptor homodimerization and negative
cooperativity. EMBO J 24: 1954–1964.
16. Latif R, Graves P, Davies TF (2002) Ligand-dependent inhibition of
oligomerization at the human thyrotropin receptor. J Biol Chem.
17. Latif R, Ando T, Davies TF (2007) Lipid rafts are triage centers for multimeric
and monomeric thyrotropin receptor regulation. Endocrinology 148:
3164–3175.
18. De MP (1976) Cooperative properties of hormone receptors in cell membranes.
J Supramol Struct 4: 241–258.
19. Chazenbalk GD, Kakinuma A, Jaume JC, McLachlan SM, Rapoport B (1996)
Evidence for negative cooperativity among human thyrotropin receptors
overexpressed in mammalian cells. Endocrinology 137: 4586–4591.
20. Calebiro D, de Filippis T, Lucchi S, Covino C, Panigone S, et al. (2005)
Intracellular entrapment of wild-type TSH receptor by oligomerization with
mutants linked to dominant TSH resistance. Hum Mol Genet 14: 2991–3002.
21. Persani L, Calebiro D, Bonomi M (2007) Technology Insight: modern methods
to monitor protein-protein interactions reveal functional TSH receptor
oligomerization. Nat Clin Pract Endocrinol Metab 3: 180–190.
22. Ando T, Latif R, Davies TF (2007) Antibody-induced modulation of TSH
receptor post-translational processing. J Endocrinol 195: 179–186.
23. Gurevich VV, Gurevich EV (2008) GPCR monomers and oligomers: it takes all
kinds. Trends Neurosci 31: 74–81.
24. Micahalek K, Latif R, Davies TF (2008) Aberrant homodimerization at the TSH
receptor: Dynamic role of beta subunit. Endocrine Society Meeting (poster).
25. Fan QR, Hendrickson WA (2005) Structure of human follicle-stimulating
hormone in complex with its receptor. Nature 433: 269–277.
26. Sanders J, Chirgadze DY, Sanders P, Baker S, Sullivan A, et al. (2007) Crystal
structure of the TSH receptor in complex with a thyroid-stimulating
autoantibody. Thyroid 17: 395–410.
27. Oda Y, Sanders J, Roberts S, Maruyama M, Kato R, et al. (1998) Binding
characteristics of antibodies to the TSH receptor. J Mol Endocrinol 20:
233–244.
28. Costa MJ, Song Y, Macours P, Massart C, Many MC, et al. (2004) Sphingolipid-
cholesterol domains (lipid rafts) in normal human and dog thyroid follicular cells
are not involved in thyrotropin receptor signaling. Endocrinology 145:
1464–1472.
29. Filizola M, Olmea O, Weinstein H (2002) Prediction of heterodimerization
interfaces of G-protein coupled receptors with a new subtractive correlated
mutation method. Protein Eng 15: 881–885.
30. Filizola M, Weinstein H (2005) The study of G-protein coupled receptor
oligomerization with computational modeling and bioinformatics. FEBS J 272:
2926–2938.
31. Periasamy A (2001) Fluorescence resonance energy transfer microscopy: a mini
review. J Biomed Opt 6: 287–291.
32. Fanelli F (2007) Dimerization of the lutropin receptor: insights from
computational modeling. Mol Cell Endocrinol 260-262: 59–64.
33. Puett D, Li Y, DeMars G, Angelova K, Fanelli F (2007) A functional
transmembrane complex: the luteinizing hormone receptor with bound ligand
and G protein. Mol Cell Endocrinol 260-262: 126–136.
34. Roess DA, Horvat RD, Munnelly H, Barisas BG (2000) Luteinizing hormone
receptors are self-associated in the plasma membrane. Endocrinology 141:
4518–4523.
35. Dohlman HG, Caron MG, DeBlasi A, Frielle T, Lefkowitz RJ (1990) Role of
extracellular disulfide-bonded cysteines in the ligand binding function of the beta
2-adrenergic receptor. Biochemistry 29: 2335–2342.
36. Lewandowicz AM, Vepsalainen J, Laitinen JT (2006) The ‘allosteric modulator’
SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-
sensitive mechanisms. Br J Pharmacol 147: 422–429.
37. Bouvier M (2001) Oligomerization of G-protein-coupled transmitter receptors.
Nat Rev Neurosci 2: 274–286.
38. Devi LA (2000) G-protein-coupled receptor dimers in the lime light. Trends
Pharmacol Sci 21: 324–326.
39. bdAlla S, Zaki E, Lother H, Quitterer U (1999) Involvement of the amino
terminus of the B(2) receptor in agonist-induced receptor dimerization. J Biol
Chem 274: 26079–26084.
40. Guan R, Wu X, Feng X, Zhang M, Hebert TE, et al. (2010) Structural
determinants underlying constitutive dimerization of unoccupied human
follitropin receptors. Cell Signal 22: 247–256.
41. Gama L, Breitwieser GE (2002) Generation of epitope-tagged proteins by
inverse polymerase chain reaction mutagenesis. Methods Mol Biol 182: 77–83.
42. Da Costa CR, Johnstone AP (1998) Production of the thyrotrophin receptor
extracellular domain as a glycosylphosphatidylinositol-anchored membrane
protein and its interaction with thyrotrophin and autoantibodies. J Biol Chem
273: 11874–11880.
43. Van DJ, Horn F, Costagliola S, Vriend G, Vassart G (2006) GRIS: glycoprotein-
hormone receptor information system. Mol Endocrinol 20: 2247–2255.
TSHR Multimerization
PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9449